To further explore the predictive efficiency of the PRL signature on different clinical characteristics from the TCGA cohort, the following clinical variables were used for analysis: age (≤65 and >65 years), FIGO stage (I–II and III–IV), pathological grade (G1–2 and G3–4), and residual tumor size (R0 and non-R0). Here, PRL is linked to neoplasm.